louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05231291: Association Between Handgrip Strength, Skinfold Thickness and Trunk Strength
Official title: Association Between Handgrip Strength, Skinfold Thickness and Trunk Strength Among University Students
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Young Adult
Keywords: Hand Grip Strength
Skinfold Thickness
Trunk strength
Lead sponsor: King Khalid University
Sponsor class: OTHER
First posted: 2022-02-09
Enrollment: 40
Sex: MALE
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: College students within the age group of 18-25 years. We were interested in looking for Association between hand grip strength , Skinfold thickness and trunk strength

Brief summary: The main objective was to explore relationship between skinfold measurement at multiple sites, hand grip strength, and trunk muscle strength (flexors and extensors) in healthy participants. Conclusion: There is a moderate association between hand grip strength, T score and trunk muscle strength, evident from the present research. Though no such association was seen for skinfold measurement.

Detailed description: Objectives: The main objective was to explore relationship between skinfold measurement at multiple sites, hand grip strength, and trunk muscle strength (flexors and extensors) in healthy participants. Methods: Cross-sectional design, randomly recruited 40 participants. Finally only 39 participants were included. Measurements for demographic variable and anthropometric variables were done. Then the evaluation for hand grip strength and skin fold was done. Data Analysis: Quantitative variables were designated using means and standard deviations, and qualitative variables described by frequencies. The Repeated measure for Analysis of Variance (RANOVA) was used to analyse whether there was statistically significant interaction between the two groups (smoking vs non-smokers). The Pearson correlation coefficient was used to measure associations of anthropometric traits with grip strength. Multiple linear regression model was also carried to explore the linear relationship between dependent and independent variables.

Eligibility criteria: Inclusion Criteria:

* This cross-sectional study Only healthy participants with no known history of previous diseases were included (n=39).

Exclusion Criteria:

* Students who found it difficult to follow the instructions for the tests after one familiarity sessions were excluded (n=0). Students reporting any kind of acute infections, previous history of chronic respiratory diseases were also excluded (n=1).

Primary outcomes:
measure: Handgrip strength
timeFrame: 1 month
measure: Trunk strength
timeFrame: 1 month
measure: Skinfold thickness
timeFrame: 1 month
Secondary outcomes:
measure: Waist Circumference
timeFrame: 1 month
measure: Smoking Habits
timeFrame: 1 month
Other outcomes:
Locations:
city: Abha
country: Saudi Arabia
facility: King Khalid University
state: Aseer
Study officials:
References:
Clinical trial NCT00404391: A Study Comparing the Analgesic Activity of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR) and Placebo in Subjects With Pain Following Bunionectomy Surgery
Official title: A Randomized, Double-Blind, Placebo-Controlled Study Comparing the Analgesic Activity of Hydrocodone/Acetaminophen Extended Release and Placebo in Subjects With Pain Following Bunionectomy Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Pain
Keywords: Moderate to severe pain following bunionectomy surgery
Lead sponsor: Abbott
Sponsor class: INDUSTRY
First posted: 2006-11-28
Enrollment: 210
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effectiveness (level of pain control) and safety of the administration of 2 different dose levels of Extended Release Hydrocodone/Acetaminophen with placebo over a 48 hour dosing period in patients who have had bunionectomy surgery, and to assess the safety of the drug for 7 days after patients are discharged from the hospital.


Eligibility criteria: Inclusion Criteria:

* Male or female ages 18 to 65
* Females must be of non-childbearing potential or practicing birth control
* Subject is scheduled to undergo primary, unilateral first metatarsal bunionectomy surgery

Exclusion Criteria:

* Is allergic to or has a serious reaction to hydrocodone, or other opioids, acetaminophen, lidocaine or propofol, and/or similar drugs
* Has initiated corticosteroid therapy within the past month or is scheduled to receive any corticosteroid during the study
* Is associated with any currently ongoing research study

Primary outcomes:
measure: Time-interval-weighted sum of pain relief (TOTPAR)score for 0 to 12 hours following the first dose of study drug administration
timeFrame: 12 hours
Secondary outcomes:
measure: Time interval weighted sum of pain intensity difference (SPID)scores
timeFrame: 12 hours
Other outcomes:
Locations:
city: Owing Mills
country: United States
facility: Site Ref # / Investigator 4993
state: Maryland
city: Austin
country: United States
facility: Site Ref # / Investigator 4994
state: Texas
city: San Marcos
country: United States
facility: Site Ref # / Investigator 4992
state: Texas
city: Salt Lake City
country: United States
facility: Site Ref # / Investigator 4995
state: Utah
Study officials:
affiliation: Abbott
name: Rita Jain, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05184491: Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management
Official title: Nitazoxanide and Lansoprazole Based Regimens for Managing Helicobacter Pylori in Egyptian Patients (NILE Study)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Helicobacter Pylori
Keywords: Helicobacter pylori
Eradication
nitazoxanide
Lansoprazole
LOAD
Lead sponsor: National Liver Institute, Egypt
Sponsor class: OTHER
Collaborators: name: Future pharmaceutical industries
First posted: 2022-01-11
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study will evaluate the eradication rate and tolerability of modified LOAD regimens (three antibiotics and a proton pump inhibitor (lansoprazole)) for management of HP infection in treatment-naive patients as well as patients who failed previous therapies.

Detailed description: This will be randomized, parallel group, comparative open-label study that will be conducted to evaluate the efficacy and tolerability of a four-drug regimen (modified LOAD regimen) in eradicating HP. The study will evaluate the efficacy of modified LOAD regimens(levofloxacin/moxifloxacin, nitazoxanide, doxycycline and lansoprazole) inpatients who failed previous therapies and compare these regimens with the classic triple therapy (amoxicillin, clarithromycin and lansoprazole) in treatment naïve patients.

Eligibility criteria: Inclusion Criteria:

* Patients presented with dyspepsia for more than one month with positive H. pylori antigen test in stool

Exclusion Criteria:

* Treatment with proton pump inhibitors, bismuth, H2 receptor antagonist, or sucralfate within the two weeks before study entry, recent use of antibiotics (within one month), allergy to any of the study drugs, active bleeding, gastric surgery, pregnancy, any current malignancy.

Primary outcomes:
measure: Number of participants with negative results of enzyme immunoassay H. pylori antigen test in stool (Monocent, Inc., CA, USA).
timeFrame: 4 weeks after completion of treatment
Secondary outcomes:
measure: Number of participants with treatment-related adverse events as assessed by Egyptian pharmacovigilance Center (EPVC) criteria
timeFrame: Through study completion, an average of 24 weeks
Other outcomes:
Locations:
city: Shibīn Al Kawm
country: Egypt
facility: National Liver institute - Menoufia University
state: Menoufia
Study officials:
affiliation: National Liver Institute
name: Gasser El-Azab, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03064191: Influence of Intra Canal Medications on Postoperative Flare-up in Endodontic Re-treatment Cases
Official title: Influence of Calcium Hydroxide Chlorhexidine Combination vs. Calcium Hydroxide as an Intra Canal Medicaments on Postoperative Flare -up Following Two-Visits Endodontic Retreatment Cases: Single Blinded Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Postoperative Pain
Pain, Dental
Keywords: intra-canal medications
Lead sponsor: Cairo University
Sponsor class: OTHER
Collaborators: name: Cairo University
First posted: 2017-02-24
Enrollment: 24
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Is to evaluate the influence of the calcium hydroxide / chlorhexidine combination and calcium hydroxide alone as an intra-canal medication in postoperative flare-up in two visits endodontic retreatment cases

Detailed description: Problem: patient needs retreatment Intervention: calcium hydroxide chlorhexidine combination as an intra-canal medicament Control: calcium hydroxide alone as an intra-canal medicament Outcome: postoperative flare-up (pain and swelling) Time: after 7 days from 1st visit. population will be examined:

1. Patients' needs retreatment.
2. Patients in good health with no systemic disease (American Society of Anesthesiologists Class II)
3. Age range is between 20 and 50 years.
4. Patients who can understand the categorical tool (points)for measurement
5. Patients able to sign informed consent.

Eligibility criteria: Inclusion Criteria:

* 1. Patients' needs retreatment.
* 2. Patients in good health with no systemic disease (American Society of Anesthesiologists Class II)
* 3. Age range is between 20 and 50 years.
* 4. Patients who can understand the categorical tool (points)for measurement
* 5. Patients able to sign informed consent.

Exclusion Criteria:

* 1) Complicating systemic disease
* 2) Having severe pain and/or acute apical abscesses
* 3) Being under 18 years of age
* 4) Using antibiotics or corticosteroids,
* 5) having multiple teeth that required retreatment to eliminate the possibility of pain referral
* 6) Having root canals that could not be treated well with initial root canal treatment.

Primary outcomes:
measure: measuring patients postoperative pain and swelling following endodontic re-treatment sessions using Categorical (4 points) unit using questionnaire.
timeFrame: 7 days between the 2 visits ( one week)
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Univeristy of Cairo
Study officials:
References:
Clinical trial NCT05008991: Lung Functions in Menopausal Obese Women After COVID 19 Recovery
Official title: Assessment of Lung Functions in Menopausal Obese Women After COVID 19 Recovery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lung Function Decreased
Obesity
Menopause
Covid19
Keywords: Lung funnctions
Menopause
Obesity
Covid19
Lead sponsor: Badr University
Sponsor class: OTHER
First posted: 2021-08-17
Enrollment: 40
Sex: FEMALE
Minimum age (years): 45
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: all women will be aged from 45 to 55 years old in menopause, their BMI will be from 30 to 34.9 kg/m2.

Brief summary: The COVID-19 pandemic has presented considerable challenges to global health services and dictates almost every aspect of medical practice and policy. The menopausal transition may have significant consequences for respiratory health as COVID 19 symptoms subsides, lung function testing should be done to assess the consequences of this virus on lung health especially in menopausal woman.

Detailed description: The study group will consist of (40) obese menopausal women whom were recently recovered from mild-moderate COVID 19 for one month. The control group will consist of (40) obese menopausal women; whom will not affected by COVID 19. Using incentive spirometer, we will measure forced vital capacity FVC, forced expiratory volume FEV, Tiffano index TI and peak expiratory force PEF in both groups.

Eligibility criteria: Inclusion Criteria:

* Participants recovered from mild to moderated signs and symptoms of COVID- 19 after one month.
* Ability to perform pulmonary function tests correctly.
* COVID-19 was diagnosed by positive polymerase chain reaction (PCR) testing on nasopharyngeal swab, oxygen saturation was ranged between 92-96% during illness period.
* CT chest shows ground glass opacity.
* Their D-dimer was less than 0.5 μg/ml.
* Two successive negative PCR were before included in study.
* Participants were in home isolation during illness period.

Exclusion Criteria:

* Chronic respiratory disease.
* Chronic heart disease.
* Diabetes mellitus.
* Smoking.
* Centralized isolation.
* Severe COVID-19.

Primary outcomes:
measure: Forced expiratory volume in the first second (FEV1)
timeFrame: FEV1 will be measured after 1 month post COVID19 recovery.
measure: forced vital capacity (FVC)
timeFrame: FVC will be measured after 1 month post COVID19 recovery.
measure: FEV1/FVC ratio
timeFrame: FEV1/FVC ratio will be measured after 1 month post COVID19 recovery.
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Physical Therapy, Badr University
state: New Cairo
Study officials:
affiliation: Badr University in Cairo
name: Mariam El Ebrashy, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05967494: Discovering Trends in Chronic Fatigue Syndrome Patients' Clinical Study Experiences
Official title: Assessing Patient Engagement and Understanding in Chronic Fatigue Syndrome Clinical Trials
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Chronic Fatigue Syndrome
Keywords: Chronic Fatigue Syndrome
Lead sponsor: Power Life Sciences Inc.
Sponsor class: INDUSTRY
First posted: 2023-08-01
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with chronic fatigue syndrome who are actively considering enrolling in a clinical study, but have not yet completed enrollment and randomization.

Brief summary: The study seeks to delve into the firsthand experiences of patients diagnosed with chronic fatigue syndrome who partake in a separate clinical trial featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals.

The data collected from this study will help improve future outcomes for all chronic fatigue syndrome patients as well as those in under-represented demographic groups.


Eligibility criteria: Inclusion Criteria:

* Signed Written Informed Consent
* Aged ≥ 18 years old
* No prior treatment for chronic fatigue syndrome

Exclusion Criteria:

* Participant is actively receiving study therapy in another
* Inability to provide written informed consent
* Women of childbearing potential without a negative pregnancy test; or women who are lactating.

Primary outcomes:
measure: Rate of patients who decide to join in a chronic fatigue syndrome clinical trial
timeFrame: 3 months
measure: Number of chronic fatigue syndrome patients who remain in clinical trial until completion
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: Power Life Sciences
state: California
Study officials:
affiliation: Power Life Sciences Inc.
name: Michael B Gill
role: STUDY_DIRECTOR
References:
citation: Meng XD, Guo HR, Zhang QY, Li X, Chen Y, Li MY, Zhuo XM, Wang MJ, Shan K, Gong YN, Li NC, Chen B, Chen ZL, Guo Y. The effectiveness of cupping therapy on chronic fatigue syndrome: A single-blind randomized controlled trial. Complement Ther Clin Pract. 2020 Aug;40:101210. doi: 10.1016/j.ctcp.2020.101210. Epub 2020 Jun 20.
citation: Kim DY, Lee JS, Park SY, Kim SJ, Son CG. Systematic review of randomized controlled trials for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). J Transl Med. 2020 Jan 6;18(1):7. doi: 10.1186/s12967-019-02196-9.
citation: Galeoto G, Sansoni J, Valenti D, Mollica R, Valente D, Parente M, Servadio A. The effect of physiotherapy on fatigue and physical functioning in chronic fatigue syndrome patients: A systematic review. Clin Ter. 2018 Jul-Aug;169(4):e184-e188. doi: 10.7417/T.2018.2076.
Clinical trial NCT03207594: Improving Evidence-Based Care for Cancer Patients
Official title: Improving Evidence-Based Care for Cancer Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Head and Neck Cancer
Prostate Cancer
Breast Cancer
Lung Cancer
Gynecologic Cancer
Gastrointestinal Cancer
Lead sponsor: Medical University of South Carolina
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
First posted: 2017-07-05
Enrollment: 128
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient who have been diagnosed with head/neck, lung, breast, prostate, gastrointestinal or gynecologic cancers that are 21 years of age or older. Patients must have been referred to MUSC radiation oncology for treatment with curative radiation therapy

Brief summary: The purpose of this study is to improve cancer care and the delivery of cancer care. Researchers are interested in studying patient reported information and examining how different factors may impact cancer care.


Eligibility criteria: Inclusion Criteria:

* Diagnosed with head/neck, lung, breast, prostate, gastrointestinal or gynecologic cancer
* 21 years of age or older at time of study registration
* Must have been referred to MUSC radiation oncology for treatment with curative radiation therapy
* Must report current smoking defined as self-reporting smoking within the past 30 days using a structured intake questionnaire.

Exclusion Criteria:

* Patients with primary central nervous system malignancies will be excluded.
* Patients that have other cancer disease types will be excluded due to either significant differences in standard radiation therapy approaches or rarity of disease required radiation.
* Patients who are currently participating in the Medical University of South Carolina Hollings Cancer Center smoking cessation program
* Patients who are unable to provide informed consent

Primary outcomes:
measure: Number of patients with biochemically confirmed smoking cessation
timeFrame: 4 weeks after enrollment
measure: Number of patient who self-report smoking cessation
timeFrame: 4 weeks after enrollment
Secondary outcomes:
measure: Average weekly smoke exposure
timeFrame: up to 62 weeks
measure: Number of patients who participate in smoking cessation
timeFrame: up to 12 months after completion of RT.
measure: Compliance with smoking cessation
timeFrame: up to 12 weeks after completion of RT
Other outcomes:
Locations:
city: Charleston
country: United States
facility: Medical University of South Carolina
state: South Carolina
Study officials:
affiliation: Medical University of South Carolina
name: Graham Warren, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00186394: High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma
Official title: High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Lymphoma, Non-Hodgkin
Blood and Marrow Transplant (BMT)
Lymphomas: Non-Hodgkin
Lead sponsor: Stanford University
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
First posted: 2005-09-16
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Maximum age (years): 61
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the role of allogeneic hematopoietic cell transplantation in the treatment of NHL.

Detailed description: To determine safety and toxicity of a regimen of high dose chemotherapy with allogeneic peripheral blood progenitor cell transplantation; determine the efficacy of the procedure by following clinical outcomes and quality of life measures; and evaluate graft versus host disease incidence and severity with regimen.

Eligibility criteria: Inclusion Criteria:Morphologically confirmed relapsed non-Hodgkin's lymphoma

Age: \>18 and \<61 years of age

Signed informed consent Exclusion Criteria:Hepatic dysfunction defined by serum transaminases \>2.5X normal values

Serum creatinine of \> 2 mg/dl or creatinine clearance \< 60 ml/min

Diseases other than non-Hodgkin's lymphoma

Prior bone marrow transplant procedure

Severe psychological or medical illness

Primary outcomes:
measure: Safety
measure: Toxicity
measure: Efficacy
Secondary outcomes:
measure: Incidence of acute and chronic GVHD
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Wen-Kai Weng
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05691894: Tracer Targeting FAP PET Imaging in Patients
Official title: Tracer Targeting FAP PET Imaging in Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Cancer
Lead sponsor: Affiliated Hospital of Jiangnan University
Sponsor class: OTHER
First posted: 2023-01-20
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This is a single arm study to evaluate the safety and biodistribution of tracer targeting FAP PET Imaging in patients


Eligibility criteria: Inclusion Criteria:

1. Patients voluntarily signed informed consent;
2. Age 18-75, male or female;
3. Patients diagnosed with cancer confirmed by histopathology or cytology;
4. At least one measurable solid lesion has been examined according RECIST1.1 standard;
5. ECOG score 0\~2.

Exclusion Criteria:

1. Recovery from major trauma (including surgery) within 4 weeks prior to study treatment;
2. Patients with systemic or locally severe infections, or other serious coexisting diseases;
3. Patients with abnormal immune function or who have recently used immunosuppressive or potentiating agents including various vaccines;
4. Patients with autoimmune diseases, including rheumatoid arthritis;
5. Inadequate control of arrhythmias, including atrial fibrillation;
6. Uncontrolled hypertension;
7. Patients with allergies or allergies to any component of the imaging agent or antibody;
8. Patients who cannot undergo PET/CT imaging scan;
9. Syphilis, HBV, HCV, or HIV positive subjects;
10. Male and female subjects of reproductive age cannot take effective contraceptive measures;
11. Pregnant or lactating women;
12. Patients with a history of mental illness or related conditions;
13. Other subjects considered unsuitable by researchers.

Primary outcomes:
measure: Evaluation of tissue distribution of 18F-FAPI
timeFrame: 1 day
measure: Evaluation of tissue distribution of 68Ga-FAPI
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Wuxi
country: China
facility: Affiliated Hospital of Jiangnan University
Study officials:
affiliation: Affiliated Hospital of Jiangnan University
name: Chunjing Yu
role: PRINCIPAL_INVESTIGATOR
References: